B.N.RATHI
SECURITIES LIMITED

B.N.Rathi Securities Ltd.

6-3-652, 4th Floor, Kautilya, Amrutha Estates, Somajiguda, Hyderabad - 500 082
Phone: +91 40 4052 7777 / 4072 7777 | www.bnrsecurities.com

MONTHLY INVESTMENT REPORT

01st Nov 2026

COMPANY NAME: Shaily Engineering Plastics Ltd

RATING: BUY | CMP: 3170 | TARGET: 3506 | TIME FRAME: 9-12 MONTHS

SECTOR: INDUSTRIAL SUPPLIERS

Why SHAILY is a BUY:

Shaily Engineering Plastics is an interesting company to evaluate from a long-term investment perspective because it operates in the specialised precision-engineering and injection-moulded plastics segment, where product quality, technical expertise, manufacturing capabilities and customer relationships create meaningful entry barriers. Unlike conventional plastic manufacturers that primarily compete on price and volumes, Shaily has developed capabilities in manufacturing complex, precision-engineered plastic components for sectors such as pharmaceuticals, medical devices, consumer products and industrial applications. Its positioning in high-value, technically demanding products provides opportunities for better realisations, stronger customer relationships and sustainable business growth. The company's exposure to the pharmaceutical and healthcare ecosystem is particularly interesting because demand for drug-delivery devices, insulin pens and other medical-device components can benefit from increasing healthcare expenditure, chronic disease prevalence and the global shift towards more sophisticated drug-delivery systems.

One of Shaily's biggest strengths is its ability to manufacture specialised plastic products that require precision engineering, advanced tooling, product development and stringent quality standards. The company works with global pharmaceutical and healthcare customers and offers integrated capabilities ranging from product design and development to manufacturing and supply. Its expertise in insulin injector pens, auto-injectors, inhalers and other drug-delivery devices makes it a specialised supplier rather than a commodity plastic manufacturer.

Unique qualities of the company:

Shaily Engineering Plastics Ltd. has several distinctive qualities that differentiate it from traditional plastic-processing companies and make it an interesting business in India's specialised manufacturing and healthcare ecosystem. Its biggest competitive advantage lies in its ability to combine precision plastic engineering, advanced product design, specialised tooling and large-scale manufacturing under one integrated business model. The company is not merely manufacturing plastic components; it is increasingly positioning itself as a technology-oriented manufacturing partner for global pharmaceutical, healthcare, consumer and industrial companies.

Shaily has developed an integrated manufacturing model that covers product conceptualisation, design, engineering, mould development, tooling, prototyping, validation and commercial production. This is an important differentiator because customers can work with a single manufacturing partner throughout the product-development cycle instead of coordinating with multiple vendors. Its in-house tooling and mould-making capabilities also allow it to manufacture complex products with high dimensional accuracy and consistency.

Why to invest in SHAILY:

Shaily Engineering Plastics Ltd. offers an interesting long-term investment opportunity because of its transformation from a conventional plastic-component manufacturer into a specialised precision-engineering and healthcare-device manufacturing company. The company's investment attractiveness comes from its exposure to high-growth healthcare markets, particularly drug-delivery devices, insulin pens and advanced auto-injectors, along with its established engineering capabilities and relationships with global pharmaceutical customers. Unlike traditional plastic manufacturers that largely depend on commodity products and price-based competition, Shaily operates in specialised segments where product development, precision engineering, quality certifications and regulatory approvals create entry barriers.

The biggest reason to invest in Shaily is its increasing exposure to the global healthcare and pharmaceutical industry. The company manufactures specialised drug-delivery devices such as insulin pens, pen injectors and auto-injectors, which are becoming increasingly important in modern healthcare. The rising incidence of diabetes, obesity and other chronic diseases is creating long-term demand for injectable drug-delivery solutions.Healthcare revenue grew approximately 78% year-on-year to ₹175.1 crore in Q2 FY27, making this segment the biggest growth contributor. This structural opportunity provides Shaily with an attractive long-term growth runway compared with conventional plastic manufacturers.

Future prospects of the company:

Healthcare is expected to remain Shaily's biggest growth driver. In FY26, healthcare revenue grew 139% to ₹392.8 crore and contributed approximately 40% of consolidated revenue. In Q2 FY27, the segment recorded another impressive 78% year-on-year growth to ₹175.1 crore. Management's medium-term ambition is for healthcare to contribute more than 50% of total company revenue. This shift towards specialised medical devices could improve the company's business quality, revenue visibility and profitability.

The global expansion of diabetes and obesity treatments presents a substantial opportunity for Shaily. Its portfolio of semaglutide pens, insulin delivery devices and reusable auto-injectors gives it exposure to this evolving market. The launch of Shaily AI Toby, a reusable two-step auto-injector platform, is particularly interesting because it offers a differentiated product proposition.

An important development is Shaily's expansion beyond its traditional healthcare, consumer and industrial businesses. Its annual report identifies precision internal components for consumer electronics and conductive chip trays for semiconductor assembly and testing as emerging commercial opportunities. These businesses could allow Shaily to participate in India's growing electronics and semiconductor manufacturing ecosystem. The diversification into these specialised applications is strategically important because it creates additional avenues for growth beyond pharmaceutical manufacturing. However, the scale and profitability of these emerging businesses will need to be established over time.

Shaily is developing into a specialised manufacturing company with exposure to three attractive areas: healthcare devices, consumer electronics and semiconductors. Its established engineering capabilities, growing healthcare business, international customer relationships and investments in advanced manufacturing infrastructure provide a foundation for future expansion.

KEY FINANCIALS TILL Q2FY27:

Consolidated Quarterly Results:

	Dec 2024	Mar 2025	Jun 2025	Jun 2025	Dec 2025	Mar 2026	Jun 2026	Sept 2026
Sales	186	203	225	236	236	224	275	310
Expenses	148	155	164	168	173	161	189	208
Operating Profit	38	48	61	68	64	63	86	101
OPM %	20%	24%	27%	29%	27%	28%	31%	33%
Other Income	0	5	2	2	0	14	0	5
Interest	4	4	4	4	4	4	3	3
Depreciation	10	10	11	11	12	12	13	13
Profit before tax	24	38	48	55	48	61	70	90
Tax %	26%	23%	25%	25%	25%	20%	25%	26%
Net Profit	18	30	36	41	36	49	52	67
EPS in Rs	3.95	6.43	7.83	8.93	7.76	10.59	11.41	14.55

Profit & Loss Statement:

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	336	361	566	600	616	738	921
Expenses	277	300	484	512	520	594	665
Operating Profit	59	60	82	88	96	144	256
OPM %	17%	17%	15%	15%	16%	20%	28%
Other Income	1	3	9	4	6	7	18
Interest	11	14	18	19	19	18	17
Depreciation	18	20	26	33	35	39	45
Profit before tax	31	30	46	40	49	95	212
Tax %	23%	26%	24%	25%	26%	25%	24%
Net Profit	24	22	35	30	36	71	161
EPS in Rs	5.67	5.29	7.66	6.53	7.88	15.43	35.1

Balance Sheet:

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8	8	9	9	9	9	9
Reserves	151	174	358	386	422	487	640
Borrowing	134	200	175	188	209	188	175
Other Liabilities	88	86	133	101	112	186	246
Total Liabilities	381	467	676	685	752	871	1,071
Fixed Assets	157	227	329	362	453	477	591
CWIP	46	30	29	55	17	18	30
Investments	0	0	9	15	21	11	11
Other Assets	178	210	309	252	261	365	439
Total Assets	8	8	9	9	9	9	9


Shareholding Pattern:

	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026	Sept 2026
Promoters	43.72%	43.72%	43.72%	43.39%	43.39%	41.09%	41.09%
FIIs	7.38%	9.71%	11.30%	12.01%	16.73%	18.18%	19.43%
DIIs	13.73%	14.13%	13.71%	13.64%	10.61%	14.84%	16.14%
Public	35.17%	32.42%	31.26%	30.97%	29.27%	25.89%	23.34%
Others	19,442	23,648	30,784	56,192	52,325	56,755	61,333
No. of Shareholders	43.72%	43.72%	43.72%	43.39%	43.39%	41.09%	41.09%

Stock price CAGR:

Stock Price CAGR	
10 Years:	38%
5 Years:	54%
3 Years:	108%
1 Year:	39%

Technical View on the Stock:



Shaily Engineering Plastics Ltd. is showing signs of a recovery in its technical structure after a period of consolidation and correction from its recent highs. As per the latest available NSE trading session on 30 October 2026, the stock closed around ₹3,170, gaining approximately 3.7% during the session. The price has moved above its short-term and medium-term moving averages, indicating improving buying interest. However, the broader trend still needs confirmation because the stock remains below its recent 52-week high of approximately ₹3,615 and momentum indicators are not uniformly bullish. The technical structure is therefore improving, but a sustained breakout above important resistance levels will be necessary to establish a stronger bullish trend.

The stock is trading above its 20-day, 50-day, 100-day and 200-day simple moving averages, which is an encouraging indication of improving price strength. The 50-day SMA is around ₹3,168, while the 100-day SMA is around ₹3,074 and the 200-day SMA is approximately ₹2,662. The stock's ability to sustain above the 50-day moving average is important because it could signal a gradual improvement in medium-term sentiment. The 200-day moving average continues to indicate a positive long-term price structure. However, a sustained upward movement with strong volumes would provide greater confirmation of a durable bullish trend.

Conclusion:

Shaily Engineering Plastics represents an interesting long-term investment opportunity within India's specialised manufacturing and healthcare ecosystem. The company's transformation from a conventional plastic-component manufacturer into a precision-engineering and medical-device manufacturing player provides a strong foundation for future growth. Its increasing exposure to global healthcare markets, particularly insulin pens, GLP-1 drug-delivery devices and advanced auto-injectors, offers significant opportunities over the next three to five years. Strong healthcare revenue growth, healthy EBITDA margins, established relationships with global pharmaceutical companies, advanced manufacturing capabilities and planned capacity expansion further strengthen its fundamental investment story.

Disclaimer:

DISCLOSURES

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

B N Rathi Securities Limited (BNRSL) is a SEBI Registered Research Analyst having registration no. INH000014687. BNRSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services and Depository participant services & BNRSL is a listed public company and the details of the company are available on www.bnrsecurities.com BNRSL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities.

BNRSL has no materialadverse disciplinary historyas on the date of publication of this report

I/We, authors(Research team) and the name/s subscribed to this report,hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subjectissuer(s) or securities. I/We also certify that nopart of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or BNRSL does not have any financial interestin the subject company. Also I/we or my/our relativeor BNRSL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of BNRSL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or BNRSL or its associates do not have any material conflict of interest. I/we have not served as director, officer or employee in the subject company.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

RESEARCH TEAM

BNRSL or its associates has not received any compensation from the subject company in the past twelve months. BNRSL or its Research Analysts has not been engaged in market making activity for the subject company.

In the last 12-monthperiod ending on the last day of the month immediately preceding the date of publication of this research report, BNRSL or any of its associates may have:

1. Received compensation for stock broking servicesor for any other servicesfrom the subjectcompany of this research report and / or;
2. Managed or co-managed public offering of the securities from the subjectcompany of this research reportand / or;
3. Received compensation for products or services other than from the subjectcompany of this research report;

BNRSL or any of its associates have not receivedcompensation or other benefitsfrom the subjectcompany of this research reportor any other third-party in connection with this report

TERMS & CONDITIONS:

This report has been preparedby BNRSL and is meant for sole use by the recipientand not for circulation. The report and information contained herein is strictlyconfidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole,to any other person or to the media or reproduced in any form,without prior written consentof BNRSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty,express or implied,is made as to its accuracy, completeness or correctness. All such information and opinions are subject to

change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Thoughdisseminated to all the customers simultaneously, not all customers may receive this reportat the same time. BNRSL will not treat recipients as customers by virtue of their receiving this report.

- Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

- This report may not be takenin substitution for the exerciseof independent judgmentby any recipient. Each recipientof this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non- investment grade securities involvesubstantial risk and are not suitable for all investors. BNRSL, its directors, analystsor employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any actiontaken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advise necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets.Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

- BNRSL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage. The recipient should take this into account before interpreting this document.

- BNRSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that BNRSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific brokerage service transactions. BNRSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

- Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender.This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contraryto law, regulation or which would subject BNRSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category on investors.
- The Disclosures of Interest Statementincorporated in this document is provided solelyto enhance the transparency and should not be treated as endorsement of the views expressed in the report.The Company reservesthe right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.
- Copyright in this document vests with B N Rathi Securities Limited Regd Off: 6-3-652, IV Floor, Kautilya Amrutha Estates, Somajiguda, Hyderabad-500082. Compliance Officer: G SabithReddy Email: compliance@bnrsecurities.com, Tel No: 9703703399

Research Entity: **B N Rathi Securities Limited**
SEBI Registration Number: **INH000014687**
CIN: L65993TG1985PLC005838

MOST IMPORTANTTERMS AND CONDITIONS (MITC)
[Formingpart of the Terms and Conditions for providing research services]

1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of, the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
2. The fee charged by RA to the clientwill be subjectto the maximum of amountprescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).

Note:

2.1.The current fee limit is Rs 1,51,000/- per annum per family of client for all researchservices of the RA.
2.2.The fee limit does not include statutory charges.
2.3.The fee limitsdo not apply to a non-individual client / accredited investor.

3. RA may charge fees in advanceif agreed by the client.Such advance shall not exceedthe period stipulated by SEBI; presently it is one quarter.In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for unexpired period.
4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
5. The RA is requiredto abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASBfrom time to time in relation to disclosure and mitigation of any actualor potential conflictof interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgment and assessment of the conclusions contained in the research report.
9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
10. For any grievances,

Step 1: the clientshould first contact the RA usingthe details on its websiteor following contactdetails: (RA to provide details as per 'Grievance Redressal / Escalation Matrix')
Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
Step 3: The clientmay also consider the Online DisputeResolution (ODR) throughthe Smart ODR portal at https://smartodr.in

11. Clients are required to keep contactdetails, including email id and mobile number/s updated with the RA at all times.
12. The RA shall never ask for the client's login credentials and OTPs for the client's Trading Account Demat Account and Bank Account. Never share such information with anyone including RA.

B.N. Rathi Securities Ltd. BNR Hyderbad

A. Satish

RESEARCH ANALYST: **SATISH KUMAR AVUSULA**